Revenue Recognition Disaggregation of Revenue by type of activity and reporting segment (Details) - USD ($)	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue [Line Items]
Net revenue	$ 982,000,000	$ 1,022,000,000
Operating Segments
Disaggregation of Revenue [Line Items]
Net revenue	982,000,000
Operating Segments Excluding Intersegment Elimination
Disaggregation of Revenue [Line Items]
Net revenue	982,000,000	$ 1,022,000,000
Greater Than One Year Member [Member]
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Percentage to be recognized over the next six months		44.00%
Biologics | Operating Segments
Disaggregation of Revenue [Line Items]
Net revenue	448,000,000	$ 523,000,000
Biologics | Manufacturing & Commercial Product Supply
Disaggregation of Revenue [Line Items]
Net revenue	282,000,000	95,000,000
Biologics | Development Services
Disaggregation of Revenue [Line Items]
Net revenue	166,000,000	428,000,000
PharmaConsumerHealth | Operating Segments
Disaggregation of Revenue [Line Items]
Net revenue	534,000,000	499,000,000
PharmaConsumerHealth | Manufacturing & Commercial Product Supply
Disaggregation of Revenue [Line Items]
Net revenue	334,000,000	314,000,000
PharmaConsumerHealth | Development Services
Disaggregation of Revenue [Line Items]
Net revenue	200,000,000	185,000,000
Total Catalent before inter-segment revenue elimination | Manufacturing & Commercial Product Supply
Disaggregation of Revenue [Line Items]
Net revenue	616,000,000	409,000,000
Total Catalent before inter-segment revenue elimination | Development Services
Disaggregation of Revenue [Line Items]
Net revenue	366,000,000	613,000,000
Total Catalent Segment | Intersegment Eliminations
Disaggregation of Revenue [Line Items]
Net revenue	$ 0	$ 0